Last reviewed · How we verify
Xanthophyll (LUTEIN)
At a glance
| Generic name | LUTEIN |
|---|---|
| Drug class | Vitamin C [EPC] |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Approved indications
- Age related macular degeneration
- Meibomian gland dysfunction
- Tear film insufficiency
Common side effects
- Appendicolith
- Blood phosphorus increased
- Appendicitis
- Ventricular fibrillation
- Cardiogenic shock
- Stress
- Myasthenia gravis
- Blood uric acid increased
- Abdominal distension
- Dry mouth
- Ascites
- Constipation
Key clinical trials
- Lutein Iontophoresis in Intermediate AMD and Reticular Pseudodrusen - a Retrospective Study
- A Clinical Study to Evaluate the Efficacy of a Nutritional Supplement to Improve Carotenoid Content as Measured by a Non-invasive Hyperspectral Absorption Device (NA)
- Effect of Carotenoids Supplementation on Visual Function in Chinese Subjects (NA)
- Sweet Corn and Carotenoids (NA)
- To Evaluate the Efficacy of Lutemax 2020 on Vision and Cognitive Performance in Health Children. (NA)
- Improved Immunology Outcomes Associated With Lactoferrin Fortified With HMO in Infant Formula (NA)
- Improved Gut Health Outcomes Associated With Probiotics Fortified With Hydrolyzed Whey Protein in Infant Formula (NA)
- Improved Cognitive Outcomes Associated With Feihe HMO With DHA/ARA in Infant Formula (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Xanthophyll CI brief — competitive landscape report
- Xanthophyll updates RSS · CI watch RSS